Mycophenolate mofetil for scleroderma-related interstitial lung disease

Affiliations

¹ Department of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Respirology, Toronto Western Hospital, Toronto, ON, Canada.
³ Division of Respirology, St Michael's Hospital, M5B 1W8, Toronto, ON, Canada. Electronic address: ananda@smh.ca.

Comment

Ahmad Zaheen et al. Lancet Respir Med. 2016 Nov.

. 2016 Nov;4(11):e53.

doi: 10.1016/S2213-2600(16)30318-6.

¹ Department of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Respirology, Toronto Western Hospital, Toronto, ON, Canada.
³ Division of Respirology, St Michael's Hospital, M5B 1W8, Toronto, ON, Canada. Electronic address: ananda@smh.ca.

No abstract available

Comment on

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators. Tashkin DP, et al. Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. Lancet Respir Med. 2016. PMID: 27469583 Free PMC article. Clinical Trial.